Document is current

Article History

Accepted: 20 February 2025

First Online: 17 March 2025

Declarations

:

: Dr. Piraccini has served as a consultant for Pierre Fabre-Ducray, Difa Cooper, Dercos-L’Oreal, ISDIN, Legacy Healthcare, Pfizer, Almirall, and Eli- Lilly; Dr. Perlis, Dr. Wolfe, Dr. Hang Nguyen, Dr. Nga Nguyen, and Dr. Zung Nguyen are shareholders of Belle.ai; Dr. Lipner has served as a consultant for Ortho-Dermatologics, Lilly, and Moberg Pharmaceuticals; Dr. Ricardo, Dr. Miller, Dr. Iorizzo, Dr. Starace, Dr. Grover, Dr. Rigopoulos, Dr. Nilton Di Chiacchio, and Dr. Nilton G. Di Chiacchio have no conflicts of interest relevant to the content of the submission.

: The research conducted in this study was generously supported by funding from Belle.ai.

: Not applicable.

: The study was conducted according to the guidelines of the Declaration of Helsinki, approved by the Institutional Review Board of Weill Cornell Medicine (IRB no. 20-10022811).

: The data analyzed in this study can be provided by the corresponding author upon reasonable request. A trial version of the AI software application can be requested by contacting BelleTorus Corp., Cambridge, Mass., by filling out a request at .

: All authors contributed substantially to this work. S.R.L. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design—S.R.L., H.N., N.N., Z.N., and C.P. Acquisition, analysis, and interpretation of data—S.R.L., J.W.R., R.M., M.I., B.M.P., M.S., C.G., D.R., N.D.C, N.G.D.C., H.N., N.N., and Z.N. Drafting of the manuscript—S.R.L. and J.W.R. Critical review of manuscript for important intellectual content—all authors. Statistical analysis—H.N., N.N., and Z.N. Obtained funding—S.R.L. Supervision—S.R.L.